Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 27, 2015Journal of Clinical OncologyOpen Access

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

View Full Paper
Ask AI
Bookmark
Share

Authors

RARobert H.I. AndtbackaHiFiBiO Therapeutics (United States)HKHoward L. KaufmanAkebia Therapeutics (United States)FCFrances A. CollichioUniversity of North Carolina Health Care

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Andtbacka et al. (2015) studied this question.

synapsesocial.com/papers/69d6bfdbfca0359822aa8314https://doi.org/10.1200/jco.2014.58.3377
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Epidemiology of Cutaneous Melanoma in Germany and Worldwide2001 · 210 citations
  2. 2Infected Cell Protein (ICP)47 Enhances Herpes Simplex Virus Neurovirulence by Blocking the CD8+ T Cell Response1998 · 201 citations
  3. 3New Perspectives on the Role of Vitiligo in Immune Responses to Melanoma2011 · 104 citations
  4. 4Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma2012 · 2,163 citations
  5. 5Functional Analysis of Tumor-Specific Th Cell Responses Detected in Melanoma Patients after Dendritic Cell-Based Immunotherapy2004 · 70 citations